NovaBridge Biosciences Statistics
Total Valuation
NBP has a market cap or net worth of $208.80 million. The enterprise value is $22.41 million.
| Market Cap | 208.80M |
| Enterprise Value | 22.41M |
Important Dates
The last earnings date was Thursday, August 20, 2026, before market open.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NBP has 116.00 million shares outstanding. The number of shares has increased by 38.28% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 116.00M |
| Shares Change (YoY) | +38.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.45% |
| Owned by Institutions (%) | 16.24% |
| Float | 64.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.64, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.64 |
| Quick Ratio | 7.58 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.10% and return on invested capital (ROIC) is -833.39%.
| Return on Equity (ROE) | -59.10% |
| Return on Assets (ROA) | -34.98% |
| Return on Invested Capital (ROIC) | -833.39% |
| Return on Capital Employed (ROCE) | -59.64% |
| Weighted Average Cost of Capital (WACC) | 12.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.92M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.29% in the last 52 weeks. The beta is 1.50, so NBP's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -61.29% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 47.63 |
| Average Volume (20 Days) | 274,933 |
Short Selling Information
The latest short interest is 4.58 million, so 6.61% of the outstanding shares have been sold short.
| Short Interest | 4.58M |
| Short Previous Month | 4.52M |
| Short % of Shares Out | 6.61% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 18.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -122.63M |
| Pretax Income | -117.55M |
| Net Income | -117.55M |
| EBITDA | -122.53M |
| EBIT | -122.63M |
| Earnings Per Share (EPS) | -$1.04 |
Balance Sheet
The company has $190.85 million in cash and $4.46 million in debt, with a net cash position of $186.39 million or $1.61 per share.
| Cash & Cash Equivalents | 190.85M |
| Total Debt | 4.46M |
| Net Cash | 186.39M |
| Net Cash Per Share | $1.61 |
| Equity (Book Value) | 201.10M |
| Book Value Per Share | 1.73 |
| Working Capital | 172.08M |
Cash Flow
In the last 12 months, operating cash flow was -$45.68 million and capital expenditures -$990,000, giving a free cash flow of -$46.67 million.
| Operating Cash Flow | -45.68M |
| Capital Expenditures | -990,000 |
| Depreciation & Amortization | 107,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -46.67M |
| FCF Per Share | -$0.40 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.28% |
| Shareholder Yield | -38.28% |
| Earnings Yield | -56.30% |
| FCF Yield | -22.35% |
Analyst Forecast
The average price target for NBP is $8.67, which is 381.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 381.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |